Source: genengnews.com<\/p>\n
A single dose of an antibody-based treatment can prevent human immunodeficiency virus (HIV) transmission from mother to baby, according to new nonhuman primate research. The findings (\u201cSingle-dose bNAb cocktail or abbreviated ART post-exposure regimens achieve tight SHIV control without adaptive immunity\u201d) were recently published in\u00a0Nature Communications. When that single dose is given is key, however. The study found rhesus macaque newborns did not develop the monkey form of HIV, called SHIV, when they received a combination of two antibodies 30 hours after being exposed to the virus.<\/p>\n
Delaying treatment until 48 hours, on the other hand, resulted in half of the baby macaques developing SHIV when they were given four smaller doses of the same antibody cocktail. In comparison, the study found macaques that received the current standard HIV treatment\u2014antiretroviral drugs\u2014remained SHIV-free when they started a three-week regimen of that therapy 48 hours after exposure.<\/p>\n
Vertical transmission accounts for most HIV infection in children, and treatments for newborns are needed to abrogate infection or limit disease progression. \u201cWe showed previously that short-term broadly neutralizing antibody (bNAb) therapy given 24\u2009h after oral exposure cleared simian-human immunodeficiency virus (SHIV) in a macaque model of perinatal infection. Here, we report that all infants given either a single dose of bNAbs at 30\u2009h, or a 21-day triple-drug ART regimen at 48\u2009h, are aviremic with almost no virus in tissues. In contrast, bNAb treatment beginning at 48\u2009h leads to tight control without adaptive immune responses in half of the animals. We conclude that both bNAbs and ART mediate effective post-exposure prophylaxis in infant macaques within 30\u201348\u2009h of oral SHIV exposure. Our findings suggest that optimizing the treatment regimen may extend the window of opportunity for preventing perinatal HIV infection when treatment is delayed,\u201d the investigators wrote.<\/p>\n
\u201cThese promising findings could mean babies born to HIV-positive mothers can still beat HIV with less treatment,\u201d said the study\u2019s corresponding\u2019s author, Nancy Haigwood, PhD, a professor of pathobiology and immunology in the Oregon Health & Science University (OHSU) School of Medicine, as well as the director at the Oregon National Primate Research Center at OHSU.<\/p>\n
This is the first time a single dose of broadly neutralizing antibodies given after viral exposure has been found to prevent SHIV infection in nonhuman primate newborns, noted the scientists. Previous research by Haigwood, Ann Hessell, PhD, a research associate professor at OHSU, and others showed four doses of antibodies started 24 hours after exposure prevented SHIV infection, with all 10 of the baby primates in that study not having any SHIV virus for six months. Both studies used a combination of two antibodies called PGT121 and VRC07-523.<\/p>\n
The new study also suggests a much shorter course of antiretroviral therapy given after virus exposure could prevent HIV transmission to newborns. Human babies born from HIV-positive mothers typically take the drug cocktail\u2014a personalized regimen of multiple drugs taken daily\u2014for about six weeks before being re-tested. If the tests are then positive, they likely need to take HIV drugs for the rest of their lives. But this study showed nonhuman primate newborns didn\u2019t have SHIV after undergoing antiretroviral therapy for just three weeks starting 48 hours after exposure.<\/p>\n
HIV-positive women typically take antiretroviral therapy drugs during pregnancy for their own health, as well as to prevent passing the virus onto their developing child. But mother-to-baby transmission sometimes still happens. Children born to HIV-positive mothers also are given antiretroviral therapy to further prevent infection. However, this drug cocktail can have many negative side effects, involves making special liquid formulations for newborns, and researchers worry about antiretroviral therapy\u2019s long-term consequences for development.<\/p>\n
Antibodies, however, generally aren\u2019t toxic and can be modified to last a long time in the body, which reduces treatment frequency. This has led researchers to explore their potential to replace or supplement antiretroviral therapy for newborns with HIV-positive mothers as well as for HIV-positive adults.<\/p>\n
Next, Haigwood and colleagues plan to see if different antibodies, or a combination of antibodies and antiretroviral therapy, could be even more effective. They also want to determine if the antibodies they evaluate actually eliminate HIV, or only prevent it from replicating. The research team has regularly shared their primate research findings with the scientific community, including those involved in the International Maternal Pediatric Adolescent AIDS Clinical Trials Network, which is currently leading two trials evaluating a single antibody to treat HIV-exposed newborns.<\/p>\n\n\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":3946,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[2576,52,222,53,184],"class_list":["post-3945","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-aids-hiv","tag-antibody","tag-hiv","tag-researchers","tag-treatment","tag-virus"],"yoast_head":"\n